Unique ID issued by UMIN | UMIN000056333 |
---|---|
Receipt number | R000064344 |
Scientific Title | Evaluation of the Clinical Usefulness of Measurement-Based and AI-Supported Care in the Treatment of Depression: An Open-Label Randomized Controlled Trial |
Date of disclosure of the study information | 2025/02/14 |
Last modified on | 2025/02/13 09:13:20 |
Evaluation of the Clinical Usefulness of Measurement-Based and AI-Supported Care in the Treatment of Depression: An Open-Label Randomized Controlled Trial
MBAIC Study
Evaluation of the Clinical Usefulness of Measurement-Based and AI-Supported Care in the Treatment of Depression: An Open-Label Randomized Controlled Trial
MBAIC Study
Japan |
Major Depressive Disorder
Psychiatry |
Others
NO
To evaluate the clinical usefulness of Measurement -Based and AI-supported care to the adult patients of major depressive disorder.
Efficacy
Shared Decision Making Scale (SDM-Q-9 or SDM-Q-Doc) score and Client Satisfaction (CSQ-8J) at the time of end of intervention period
1. Coincident ratio between patient shared decision making (DSM-Q-9) and physician shared decision making (SDM-Q-Doc)
2. Remission rate of depression
3. Tool issues, frequency of tool use
4. Trust in physicians (TPS)
5. Depressive symptoms (HAMD, MADRS, BDI-II)
6. Satisfaction with the care using the tool (CSQ-8J)
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
NO
Central registration
2
Treatment
Other |
Measurement -Based and AI-supported care along with usual care
Treatment as usual
18 | years-old | <= |
75 | years-old | > |
Male and Female
(Patients)
1. Those who meet the diagnostic criteria for depression in DSM-5
2. Those who understand the purpose and content of this study and have obtained written consent from the individual to participate in the study of their own free will
(Medical Doctors)
1. Outpatient doctors who are in charge of above patient
2. Those who understand the purpose and content of this study and have obtained written consent from the individual to participate in the study of their own free will
(Patients)
1. Those with a history of severe organic brain lesions or cognitive dysfunction
2. Those with a clinically diagnosed life-threatening or unstable physical condition at the time of screening
3. Those who are unable to visit the hospital more than twice within 3 months of participation in the study
4. Others deemed by the principal investigator to be ineligible for the study
(Medical Doctors)
N/A
48
1st name | Toshiaki |
Middle name | |
Last name | Kikuchi |
Keio University of Medicine
Department of Neuropsychiatry
160-8582
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-5363-3971
t-kick.z3@keio.jp
1st name | Toshiaki |
Middle name | |
Last name | Kikuchi |
Keio University School of Medicine
Department of Neuropsychiatry
160-8582
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-5363-3971
t-kick.z3@keio.jp
Keio University
Japan Agency for Medical Research and Development (AMED)
Japanese Governmental office
Himorogi Psychiatric Institute
Research Ethics Committee of Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku, Tokyo
03-3353-1211(ex62014)
med-rinri-jimu@adst.keio.ac.jp
NO
2025 | Year | 02 | Month | 14 | Day |
Unpublished
Preinitiation
2025 | Year | 02 | Month | 01 | Day |
2025 | Year | 02 | Month | 05 | Day |
2025 | Year | 03 | Month | 01 | Day |
2025 | Year | 12 | Month | 31 | Day |
2024 | Year | 12 | Month | 02 | Day |
2025 | Year | 02 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064344